Mesoblast draws US$50 million to retire debt and fund growth
Mesoblast Limited drew down US$50 million from a five-year facility provided by Dr. Gregory George at 8.00% fixed interest to retire higher-cost debt. The facility is secured by the Temcell royalty and has no prepayment fees. The company reported cash reserves of US$122 million as of March 30, 2026.
*this image is generated using AI for illustrative purposes only.
Mesoblast Limited has drawn down US$50 million from a five-year facility provided by existing shareholder and director Dr. Gregory George. The transaction, announced on June 24, 2026, strengthens the company's balance sheet by retiring higher cost debt and optimizing its capital structure. Mesoblast reported cash reserves of US$122 million as of March 30, 2026, positioning it to invest in commercial operations and its growth pipeline.
The new credit-line features a fixed interest rate of 8.00% per annum, a substantial reduction from prior facilities. It includes a five-year interest-only period from the initial draw and is secured solely by the Temcell royalty. The facility can be repaid at any time without incurring early prepayment, make-whole, or exit fees.
Key Facility Details
| Feature | Details |
|---|---|
| Facility Amount | US$50 million |
| Tenor | Five years |
| Interest Rate | 8.00% per annum (fixed) |
| Interest Period | Five years (interest only) |
| Security | Temcell royalty |
| Prepayment Fees | None |
Mesoblast Chief Executive Silviu Itescu stated that the favorable long-term facility eliminates short-term high-cost debt. He noted that the facility does not encumber any material assets or intellectual property, enabling unrestricted entry into strategic partnerships or licensing transactions. The company intends to use the funds to retire the NovaQuest Capital Management LLC debt facility, thereby eliminating short-term debt obligations.
How will the elimination of the NovaQuest debt facility impact Mesoblast's quarterly cash burn and overall financial runway?
What specific commercial operations or pipeline assets will the company prioritize for investment with the strengthened balance sheet?
Does the unencumbered status of Mesoblast's intellectual property signal an imminent strategic partnership or licensing deal?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
